drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous gene-modified T lymphocytes engineered to express chimeric antigen receptors that recognize tumor antigens independently of MHC, leading to potent T-cell activation and antitumor activity; associated with cytokine release syndrome and potential cardiotoxic effects.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express chimeric antigen receptors (scFv-based receptors with CD3ΞΆ and costimulatory domains such as CD28 or 4-1BB) that bind tumor-associated surface antigens independently of MHC. Antigen engagement triggers potent T-cell activation, expansion, and cytotoxic killing of target cells via perforin/granzyme and cytokine release, which can cause cytokine release syndrome and potential cardiotoxic effects.
drug_name
Chimeric Antigen Receptor (CAR) T cells
nct_id_drug_ref
NCT06350994